Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03856372
Other study ID # FDRT-BC008
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date September 1, 2018
Est. completion date October 30, 2028

Study information

Verified date February 2019
Source Fudan University
Contact Jinli Ma, MD, PhD
Phone +86-15221033376
Email jinli.ma@aliyun.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study was designed to investigate whether hypofractionated adjuvant radiotherapy is noninferior to conventionally fractionated adjuvant radiotherapy in terms of efficacy and toxicities for high risk breast cancer patients treated with mastectomy


Description:

The randomization is between 50 Gy / 25 fractions and 42.5 Gy/16 fractions, 5 fractions weekly.

Eligible breast cancer patients with mastectomy and axillary dissection will be randomized 1:1 into two groups: conventional fractionated (CF) radiotherapy of 50 Gy / 25 fractions and hypofractionated (HF) radiotherapy of 42.5 Gy/16 fractions, 5 fractions weekly.

The primary endpoint is loco-regional recurrence. Other cancer related events and acute/late radiation morbidities will also be evaluated. The patients will be followed for 10 years.

It is hypothesized that for women operated for high risk breast cancer with indication of postmastectomy adjuvant radiotherapy, hypofractionated radiotherapy is noninferior to conventional fractionated radiotherapy in terms of the efficacy and toxicities.


Recruitment information / eligibility

Status Recruiting
Enrollment 1494
Est. completion date October 30, 2028
Est. primary completion date September 30, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- Female

- Age18-75 years

- Pathologically confirmed invasive breast cancer

- Treated with mastectomy and axillary lymph node dissection with more than 10 resected lymph nodes. Immediate or delayed ipsilateral breast cancer reconstruction is accepted

- Negative surgical margins

- Pathologic T1-2N1 with at least one of the following risk factors: <40 years, Grade 3, lymphovascular invasion positive, ER/PR negative or HER2 overexpression, or pT3-4, or pN2-3 (four or more positive axillary lymph nodes)

- No distant metastases

- No supraclavicular or internal mammary nodes metastases

- ECOG:0-1

- Adjuvant systemic therapy with chemotherapy, endocrine therapy and anti-HER2 treatment is accepted.

- No neoadjuvant chemotherapy

- Fit for postoperative radiotherapy. No contraindications to radiotherapy

- Signed informed consent

Exclusion Criteria:

- Concurrent or previous malignancy excluding basal or squamous cell carcinoma of the skin

- Previous radiotherapy to the chest wall or regional lymph node areas

- Patients with severe non-malignant comorbidity in cardiovascular or respiration system

- Patients with medical contraindication for radiotherapy: systemic lupus erythematosus, cirrhosis

- pT1-2N1 with none of the following risk factors: <40 years, Grade 3, lymphovascular invasion positive, ER/PR negative or HER2 overexpression

- Patients with supraclavicular or internal mammary nodes metastases

- Known definitive clinical or radiologic evidence of metastatic disease

- Bilateral breast cancer or historically confirmed contralateral invasive breast cancer

- Treated with neoadjuvant chemotherapy

- ECOG: 3-4

- Pregnant or lactating

- Conditions indicating that the patient cannot go through the radiation therapy or follow up

- Unable or unwilling to sign informed consent

Study Design


Related Conditions & MeSH terms


Intervention

Radiation:
Hypofractionated
daily fractions, five fractions per week.
Conventional
daily fractions, five fractions per week.

Locations

Country Name City State
China Fudan University Shanghai Cancer Center Shanghai Shanghai
China Huangpu Branch, Shanghai ninth people's hospital Shanghai Shanghai
China Suzhou Municipal hospital Suzhou Jiangsu

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Loco-regional recurrence (LRR) Defined as any clinical and biopsy-proven tumor recurrence involving the ipsilateral chest wall and/or regional nodes (including axillary, supraclavicular, infraclavicular, or internal mammary nodes). Time to loco-regional recurrence is defined as the interval starting from the date of randomization until the event. LRR will be assessed every 3 months during the first 2 years after the last fraction received, every 6 months during the following 3-5 years and every year thereafter through 10 years every 3 months during the first 2 years after the last fraction received, every 6 months during 3-5 years, every year during 6-10 years
Secondary Distant metastasis free survival (DMFS) Distant metastasis is defined as clinical detection of metastatic disease beyond the chest wall and/or regional lymph nodes or death or last visit. Distant metastasis free survival (DMFS) is defined as the interval starting from the date of randomization until to the event. Distant metastasis will be assessed every 3 months during the first 2 years after the last fraction received, every 6 months during the following 3-5 years and every year thereafter through 10 years. every 3 months during the first 2 years after the last fraction received, every 6 months during 3-5 years, every year during 6-10 years
Secondary Disease free survival (DFS) Defined as the interval from the date of randomization to any disease recurrence or death or last visit. It will be assessed every 3 months during the first 2 years after the last fraction received, every 6 months during the following 3-5 years and every year thereafter through 10 years every 3 months during the first 2 years after the last fraction received, every 6 months during 3-5 years, every year during 6-10 years
Secondary Overall survival (OS) Defined as the interval from the date of randomization to death or last visit. It will be assessed every 3 months during the first 2 years after the last fraction received, every 6 months during the following 3-5 years and every year thereafter through 10 years every 3 months during the first 2 years after the last fraction received, every 6 months during 3-5 years, every year during 6-10 years
Secondary CTCAE Toxicity Assessment-Acute toxicity Acute toxicity (development of radiation dermatitis, pruritus, pain, radiation esophagitis, and radiation pneumonitis) will be assessed according to toxicity criteria of CTCAE version 4.03 before treatment, every week of treatment, the end of treatment, 2 weeks, 3 months after the last fraction received and every year thereafter through 10 years before treatment, every week of treatment, the end of treatment, 2 weeks, 3 months after the last fraction received, every year through 10 years
Secondary CTCAE Toxicity Assessment-Late toxicity Late toxicity (development of sclerosis in irradiated area and ischemic heart disease) will be assessed according to toxicity criteria of CTCAE version 4.03 before treatment and every year through 10 years following the completion of radiotherapy before treatment, every year after the last fraction received through 10 years
Secondary LENT-SOMA Toxicity Assessment Development of dyspigmentation, telangiectasia in irradiated area and radiation pulmonary fibrosis will be assessed according to toxicity criteria of LENT-SOMA before treatment and every year through 10 years following the completion of radiotherapy before treatment, every year after the last fraction received through 10 years
Secondary Number of patients with Arm Lymphedema Arm lymphedema defined as =10% increase in the treated arm circumference over baseline circumference compared to the contralateral arm. Arm circumference 15 cm above the medial epicondyle (upper arms) and 15 cm below the medial epicondyle (lower arms) will be measured before treatment and every year through 10 years following the completion of radiotherapy at every time point before treatment, every year after the last fraction received through 10 years
Secondary Number of patients with impaired shoulder movement (Range of motion of the shoulders) Impaired shoulder movement is present when >20 degrees difference between arms at flexion and/or Abduction. Shoulder movement (Range of motion of the shoulders) will be assessed before treatment and every year through 10 years following the completion of radiotherapy before treatment, every year after the last fraction received through 10 years
Secondary Number of patients with symptomatic rib fracture Symptomatic rib fracture will be diagnosed by evidence of a correlative lesion on plain film or CT. It will be assessed before treatment and every year through 10 years following the completion of radiotherapy before treatment, every year after the last fraction received through 10 years
Secondary Number of patients with brachial plexopathy Brachial plexopathy will be documented if damage to the brachial plexus is suspected and patients have symptoms of pain, paresthesia, numbness, or other symptoms. Suspected cases of brachial plexopathy will be subject to confirmation by neurophysiological assessment. Brachial plexopathy will be assessed before treatment and every year through 10 years following the completion of radiotherapy before treatment, every year after the last fraction received through 10 years
Secondary Number of patients with reconstruction complications For patients received mastectomy and reconstruction, the following complications will be assessed before treatment and every year through 10 years following the completion of radiotherapy: capsular contraction, partial or entire flap necrosis or loss, implant leakage and rupture, implant exposure, infection, hematoma/seroma and secondary surgical intervention before treatment, every year after the last fraction received through 10 years
Secondary Cosmetic outcomes for patients received mastectomy with reconstruction The cosmetic outcomes will be evaluated by radiation oncologists, nurses and patients using digital photographs and Harvard/NSABP/RTOG Breast Cosmesis Grading Scale. Harvard/NSABP/RTOG Breast Cosmesis Grading Scale classifies the overall aesthetic results in four categories from excellent, good, fair to poor; comparing the reconstructed breast to the control breast. Excellent, there is minimal or no difference in the size or shape of the treated breast; good, slight difference in the size or shape of the treated breast; fair, obvious difference in the size or shape of the treated breast; and poor, marked change in the size or shape of the treated breast. The cosmetic outcomes will be assessed before treatment and every year through 10 years following the completion of radiotherapy. The breast cosmetic outcome will be measured by Harvard 4 scale (poor, fair, good, excellent) evaluation system before treatment, every year after the last fraction received through 10 years
Secondary Quality of Life Life-EORTC QLQ-C30 (version 3) Patients' quality of life will be assessed using self-administered questionnaire EORTC-QLQ-C30 (version 3) before treatment, the end of treatment, and every year through 10 years following the completion of radiotherapy before treatment, the end of treatment, every year after the last fraction received through 10 years
Secondary Quality of Life-EORTC breast-cancer module (BR23) Patients' quality of life will be assessed using self-administered questionnaire EORTC breast-cancer module (BR23) before treatment, the end of treatment, and every year through 10 years following the completion of radiotherapy before treatment, the end of treatment, every year after the last fraction received through 10 years
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Active, not recruiting NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - Clinical and Biological Predictors of Chemotherapy Toxicity in Older Adults
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Enrolling by invitation NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Active, not recruiting NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Recruiting NCT04190381 - A Study to Evaluate the Safety and Clinical Outcome of Using FR-Mask in Breast Cancer Patients With Radiation-irritated Skin After Radiotherapy N/A
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT02894398 - Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant Phase 2
Completed NCT01857193 - Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer Phase 1